200 related articles for article (PubMed ID: 25478810)
1. A new Mdr2(-/-) mouse model of sclerosing cholangitis with rapid fibrosis progression, early-onset portal hypertension, and liver cancer.
Ikenaga N; Liu SB; Sverdlov DY; Yoshida S; Nasser I; Ke Q; Kang PM; Popov Y
Am J Pathol; 2015 Feb; 185(2):325-34. PubMed ID: 25478810
[TBL] [Abstract][Full Text] [Related]
2. Knockout of the Tachykinin Receptor 1 in the Mdr2
Ceci L; Francis H; Zhou T; Giang T; Yang Z; Meng F; Wu N; Kennedy L; Kyritsi K; Meadows V; Wu C; Liangpunsakul S; Franchitto A; Sybenga A; Ekser B; Mancinelli R; Onori P; Gaudio E; Glaser S; Alpini G
Am J Pathol; 2020 Nov; 190(11):2251-2266. PubMed ID: 32712019
[TBL] [Abstract][Full Text] [Related]
3. Extrahepatic platelet-derived growth factor-β, delivered by platelets, promotes activation of hepatic stellate cells and biliary fibrosis in mice.
Yoshida S; Ikenaga N; Liu SB; Peng ZW; Chung J; Sverdlov DY; Miyamoto M; Kim YO; Ogawa S; Arch RH; Schuppan D; Popov Y
Gastroenterology; 2014 Dec; 147(6):1378-92. PubMed ID: 25173753
[TBL] [Abstract][Full Text] [Related]
4. Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes.
Popov Y; Patsenker E; Fickert P; Trauner M; Schuppan D
J Hepatol; 2005 Dec; 43(6):1045-54. PubMed ID: 16223543
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2
Hall C; Ehrlich L; Meng F; Invernizzi P; Bernuzzi F; Lairmore TC; Alpini G; Glaser S
J Surg Res; 2017 Sep; 217():160-169. PubMed ID: 28602220
[TBL] [Abstract][Full Text] [Related]
6. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies.
Popov Y; Patsenker E; Stickel F; Zaks J; Bhaskar KR; Niedobitek G; Kolb A; Friess H; Schuppan D
J Hepatol; 2008 Mar; 48(3):453-64. PubMed ID: 18221819
[TBL] [Abstract][Full Text] [Related]
7. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis.
Henkel C; Roderfeld M; Weiskirchen R; Berres ML; Hillebrandt S; Lammert F; Meyer HE; Stühler K; Graf J; Roeb E
Proteomics; 2006 Dec; 6(24):6538-48. PubMed ID: 17109383
[TBL] [Abstract][Full Text] [Related]
8. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
[TBL] [Abstract][Full Text] [Related]
9. Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2
Zhou T; Wu N; Meng F; Venter J; Giang TK; Francis H; Kyritsi K; Wu C; Franchitto A; Alvaro D; Marzioni M; Onori P; Mancinelli R; Gaudio E; Glaser S; Alpini G
Lab Invest; 2018 Nov; 98(11):1449-1464. PubMed ID: 29977037
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/- mice.
Roderfeld M; Rath T; Voswinckel R; Dierkes C; Dietrich H; Zahner D; Graf J; Roeb E
Hepatology; 2010 Jan; 51(1):267-76. PubMed ID: 19827165
[TBL] [Abstract][Full Text] [Related]
12. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
Ravichandran G; Neumann K; Berkhout LK; Weidemann S; Langeneckert AE; Schwinge D; Poch T; Huber S; Schiller B; Hess LU; Ziegler AE; Oldhafer KJ; Barikbin R; Schramm C; Altfeld M; Tiegs G
J Hepatol; 2019 Oct; 71(4):773-782. PubMed ID: 31173810
[TBL] [Abstract][Full Text] [Related]
14. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
15. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice.
Nishio T; Hu R; Koyama Y; Liang S; Rosenthal SB; Yamamoto G; Karin D; Baglieri J; Ma HY; Xu J; Liu X; Dhar D; Iwaisako K; Taura K; Brenner DA; Kisseleva T
J Hepatol; 2019 Sep; 71(3):573-585. PubMed ID: 31071368
[TBL] [Abstract][Full Text] [Related]
16. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
18. β-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis.
Strack I; Schulte S; Varnholt H; Schievenbusch S; Töx U; Wendland K; Steffen HM; Drebber U; Dienes HP; Odenthal M
Lab Invest; 2011 Feb; 91(2):252-61. PubMed ID: 20921947
[TBL] [Abstract][Full Text] [Related]
19. The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice.
Wu N; Meng F; Invernizzi P; Bernuzzi F; Venter J; Standeford H; Onori P; Marzioni M; Alvaro D; Franchitto A; Gaudio E; Glaser S; Alpini G
Hepatology; 2016 Sep; 64(3):865-79. PubMed ID: 27115285
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
Ikenaga N; Peng ZW; Vaid KA; Liu SB; Yoshida S; Sverdlov DY; Mikels-Vigdal A; Smith V; Schuppan D; Popov YV
Gut; 2017 Sep; 66(9):1697-1708. PubMed ID: 28073888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
